Macugen
(Pegaptanib sodium)PreclinicalSmall molecule
PfizerPegaptanib sodium is used to treat a type of vision loss caused by wet age-related macular degeneration, a disease where abnormal blood vessels grow under the retina and damage central vision in older adults.[1] Macugen is currently being investigated across 3 indications[3], with its most advanced program in Preclinical.[1]
Macugen is one of 19 small molecule programs targeting Wet Macular Degeneration. It is currently in Preclinical.
3
Indications
20
Total Trials
0
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Macular Degeneration
#DrugCompanyPhaseTrials
1Vabysmo
RocheApproved
Copaxone
TevaApproved
Iheezo
BB. Braun Medical Inc.
Approved
Avastin
RochePhase 3
Visudyne
BBausch Health Americas, Inc.
Approved
Caverject
VViatris Specialty LLC
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
OTX-TKI
OOcular Therapeutix, Inc.
Phase 3
Tiespectus
EEyeBiotech Ltd.
Phase 3
Faricimab Injection [vabysmo]
CCincinnati Eye Institute, Southwest Ohio
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Age-Related Macular Degeneration6 trials
Diabetic Macular Edema2 trials
Safety and Efficacy2 trials
7 more indications
Neovascular AMD1 trial
DME1 trial
Efficacy and Safety1 trial
Cystoid Macular Edema1 trial
Cataract1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pegaptanib sodium. EMBL-EBI & Wellcome Sanger Institute.
- [4]